Omeros Raises $63 Million

Omeros Corp., a Seattle-based drug company focused on receptor and enzyme therapeutics, has raised in excess of $63 million in Series E funding. We reported last summer that it had secured $44 million of the round, according to a regulatory filing that indicated a $75 million cap. New backers included Aravis Ventures, ARCH Venture Partners, American Financial Group, Grosvenor Funds, Novartis Venture Fund, Southern Cross Capital, Stanley Medical Research Institute, Trevi Health Ventures and WRF Capital. The round also included return backers, although Omeros died not specify which ones. Omeros now has raised $108 million in total VC funding. www.omeros.com